{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:40:31Z","timestamp":1789202431626,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11926-018-0798-1","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T05:46:41Z","timestamp":1540964801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Anti-MDA5 Antibody Spectrum in Western World"],"prefix":"10.1007","volume":"20","author":[{"given":"Siamak","family":"Moghadam-Kia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"798_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975a;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"798_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975b;292:403\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"798_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Sen\u00e9cal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231\u201349.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"798_CR4","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/ar2276","volume":"9","author":"M Koenig","year":"2007","unstructured":"Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Sen\u00e9cal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9(4):R78.","journal-title":"Arthritis Res Ther"},{"key":"798_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571\u20136.","journal-title":"Arthritis Rheum"},{"key":"798_CR6","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60:2193\u2013200.","journal-title":"Arthritis Rheum"},{"key":"798_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"798_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2010","unstructured":"Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010 Mar;49(3):433\u201340.","journal-title":"Rheumatology (Oxford)"},{"key":"798_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391\u20138.","journal-title":"Arch Dermatol"},{"key":"798_CR10","first-page":"30","volume":"49","author":"K Nagata","year":"2011","unstructured":"Nagata K, Tomii K, Nanjo S, Kubota M, Tachikawa R, Nishio M. Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody. Nihon Kokyuki Gakkai Zasshi. 2011;49:30\u20136.","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"issue":"9","key":"798_CR11","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012 Sep;51(9):1563\u201370.","journal-title":"Rheumatology (Oxford)"},{"key":"798_CR12","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013;65:1316\u201324.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"798_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098824","volume":"9","author":"T Fujisawa","year":"2014","unstructured":"Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9:e98824.","journal-title":"PLoS One"},{"key":"798_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0190-9622(91)70153-S","volume":"24","author":"RL Euwer","year":"1991","unstructured":"Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991;24:959\u201366.","journal-title":"J Am Acad Dermatol"},{"key":"798_CR15","volume-title":"Arthritis and allied conditions: a textbook of rheumatology","author":"C Pearson","year":"1979","unstructured":"Pearson C. Arthritis and allied conditions: a textbook of rheumatology. 9th ed. Philadelphia, PA: Lea & Febiger; 1979.","edition":"9"},{"key":"798_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626\u201336.","journal-title":"J Am Acad Dermatol"},{"key":"798_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","volume":"54","author":"P Gerami","year":"2006","unstructured":"Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597\u2013613.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"798_CR18","doi-asserted-by":"publisher","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285","volume":"11","author":"S Sato","year":"2016","unstructured":"Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One. 2016 Apr 26;11(4):e0154285.","journal-title":"PLoS One"},{"issue":"3","key":"798_CR19","first-page":"RA27","volume":"14","author":"AG Tristano","year":"2008","unstructured":"Tristano AG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit. 2008 Mar;14(3):RA27\u201336.","journal-title":"Med Sci Monit"},{"key":"798_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25\u201334.","journal-title":"J Am Acad Dermatol"},{"key":"798_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65:1307\u201315.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"798_CR22","first-page":"891","volume":"32","author":"A Ceribelli","year":"2014","unstructured":"Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis. Clin Exp Rheumatol. 2014 Nov-Dec;32(6):891\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"798_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016 May;68(5):689\u201394.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"798_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north American patients with dermatomyositis. J Rheumatol. 2017 Mar;44(3):319\u201325.","journal-title":"J Rheumatol"},{"issue":"3","key":"798_CR25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","volume":"186","author":"Y Allenbach","year":"2016","unstructured":"Allenbach Y, Leroux G, Su\u00e1rez-Calvet X, Preusse C, Gallardo E, Hervier B, et al. French myositis network dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol. 2016 Mar;186(3):691\u2013700.","journal-title":"Am J Pathol"},{"issue":"9","key":"798_CR26","first-page":"1719","volume":"32","author":"H Kameda","year":"2005","unstructured":"Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719\u201326.","journal-title":"J Rheumatol"},{"issue":"2","key":"798_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3109\/s10165-011-0502-z","volume":"22","author":"Y Matsuki","year":"2012","unstructured":"Matsuki Y, Yamashita H, Takahashi Y, Kano T, Shimizu A, Itoh K, et al. Diffuse alveolar damage in patients with dermatomyositis: a six-case series. Mod Rheumatol. 2012;22(2):243\u20138.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"798_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/RHU.0000000000000487","volume":"23","author":"W Shimojima","year":"2017","unstructured":"Shimojima W, Ishii M, Matsuda DK, Ikeda SI. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis. J Clin Rheumatol. 2017;23(2):87\u201393.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"798_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000346573","volume":"225","author":"A Clottu","year":"2012","unstructured":"Clottu A, Laffitte E, Prins C, Chizzolini C. Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology. 2012;225(4):376\u201380.","journal-title":"Dermatology"},{"issue":"3","key":"798_CR30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/14397595.2015.1012797","volume":"26","author":"R Watanabe","year":"2016","unstructured":"Watanabe R, Ishii T, Araki K, Ishizuka M, Kamogawa Y, Fujita Y, et al. Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2016;26(3):465\u20136.","journal-title":"Mod Rheumatol"},{"issue":"8","key":"798_CR31","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s10067-015-2928-8","volume":"35","author":"B Gil","year":"2016","unstructured":"Gil B, Merav L, Pnina L, Chagai G. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol. 2016;35(8):2125\u201330.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"798_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","volume":"27","author":"Y Koichi","year":"2017","unstructured":"Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27(3):536\u201340.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"798_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","volume":"56","author":"K Tokunaga","year":"2017","unstructured":"Tokunaga K, Hagino N. Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med. 2017;56(11):1399\u2013403.","journal-title":"Intern Med"},{"key":"798_CR34","volume":"2017","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, Kishida D, Shimojima Y, Hayashi K, Sekijima Y. Effective administration of rituximab in anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review. Case Rep Rheumatol. 2017;2017:5386797.","journal-title":"Case Rep Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0798-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0798-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T10:49:56Z","timestamp":1605350996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0798-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0798-1","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]},"assertion":[{"value":"31 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"78"}}